Gotowe bibliografie tematyczne / Disease management / Artykuły w czasopismach

Artykuły w czasopismach na temat „Disease management”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Disease management.
Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 29 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Disease management”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Jagota, Roma. "Homoeopathic Management of Meniere's Disease". International Journal of Science and Research (IJSR) 13, nr 7 (5.07.2024): 895–96. http://dx.doi.org/10.21275/sr24717175319.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Zinkernagel, V., H. Hausladen i H. Habermeyer. "Practical application of integrated disease management". Plant Protection Science 38, SI 1 - 6th Conf EFPP 2002 (1.01.2002): 212–20. http://dx.doi.org/10.17221/10358-pps.

Pełny tekst źródła
Streszczenie:
A decision support system for cereal diseases and late blight of potatoes has been developed at the Chair of Phytopathology,<br />Technische Universität München. The Wheat and Barley Prognosis System has been in use for many years by the<br />Bavarian official advisory service. It is based on an exact diagnosis and established biological thresholds influenced by<br />weather. Certain fungicides are recommended also covering diseases which have not reached the threshold. Diseases under<br />consideration are eye spot disease, powdery mildew, Septoria leaf blotch, Septoria leaf and glume blotch, tan spot, brown<br />and yellow rusts.The PhytophthoraModel Weihenstephan consists of two parts, weather based prognosis and monitoring in<br />the unsprayed control plots. Spraying recommendations are given based on the results of the above-mentioned parts and<br />considering cultivar behaviour and blight development in the field. The first spraying in the season as well as the timing<br />of the following ones are crucial. This model does not give any recommendations regarding which active ingredient should<br />applied. However there is a distinction made with regard to contact (protective) fungicides and systemic fungicides. The<br />PhytophthoraModel Weihenstephan has been in use for several years in Germany as well as in Austria.
Style APA, Harvard, Vancouver, ISO itp.
3

Kesteloot, Katrien. "DISEASE MANAGEMENT". International Journal of Technology Assessment in Health Care 15, nr 3 (lipiec 1999): 506–19. http://dx.doi.org/10.1017/s0266462399015366.

Pełny tekst źródła
Streszczenie:
Recently, many disease management programs, especially for patients with chronic diseases, have emerged. This paper discusses the potential benefits and disadvantages of disease management, on the basis of an extensive literature review. Disease management is an innovative technology in health care management, which is diffusing throughout the health care system without critical evaluation. Evidence on its effectiveness and costs is still very scarce, while the legal, ethical, organizational, and social implications of this practice have not been analyzed seriously. Before disease management is implemented on a broader scale in different European settings, first, empirical evidence about its alleged benefits and cost-effectiveness should be collected.
Style APA, Harvard, Vancouver, ISO itp.
4

Shabir, Morgan. "Cognitive impairment in Parkinson’s disease: Multidisciplinary Symposium Clinical Management of Parkinson’s disease". Neuroscience and Neurological Surgery 1, nr 3 (10.08.2017): 01–03. http://dx.doi.org/10.31579/2578-8868/022.

Pełny tekst źródła
Streszczenie:
People with Parkinson’s disease (PD) and their care partners frequently report cognitive decline as one of their greatest concerns. Mild cognitive impairment affects approximately 20–50% of people with PD, and longitudinal studies reveal dementia in up to 80% of PD. Through the Parkinson’s Disease Foundation Community Choice Research Award Program, the PD community identified maintaining cognitive function as one of their major unmet needs. In response, a working group of experts across multiple disciplines was organized to evaluate the unmet needs, current challenges, and future opportunities related to cognitive impairment in PD. Specific conference goals included defining the current state in the field and gaps regarding cognitive issues in PD from patient, care partner, and healthcare professional viewpoints; discussing non-pharmacological interventions to help maintain cognitive function; forming recommendations for what people with PD can do at all disease stages to maintain cognitive health; and proposing ideas for how healthcare professionals can approach cognitive changes in PD. This paper summarizes the discussions of the conference, first by addressing what is currently known about cognitive dysfunction in PD and discussing several non-pharmacological interventions that are often suggested to people with PD. Second, based on the conference discussions, we provide considerations for people with PD for maintaining cognitive health and for healthcare professionals and care partners when working with people with PD experiencing cognitive impairment. Furthermore, we highlight key issues and knowledge gaps that need to be addressed in order to advance research in cognition in PD and improve clinical care.
Style APA, Harvard, Vancouver, ISO itp.
5

N.I., Zakirova. "MANAGEMENT OF PREGNANT WOMEN WITH THYROID DISEASE". Frontline Medical Sciences and Pharmaceutical Journal 02, nr 03 (1.03.2022): 122–27. http://dx.doi.org/10.37547/medical-fmspj-02-03-13.

Pełny tekst źródła
Streszczenie:
The course of pregnancy, thyroid status, hormonal levels were studied in 96 women with autoimmune thyroiditis (AIT). It was found that pregnant women have a number of complications (54.8%) from the mother and the fetus, AIT has an unfavorable effect on the course of pregnancy, there is a high risk of miscarriage and termination of pregnancy, there is a decrease in the level of thyroid hormones and an increase in the level of TSH in comparison with similar indicators of healthy pregnant women. For the prevention of complications of gestation and prematurity of pregnancy in women with AIT, a planned determination of TSH blood from early gestation is recommended.
Style APA, Harvard, Vancouver, ISO itp.
6

Lazak, Fatima Zahae, i Redoune Moutj. "EPIDEMIOLOGICAL AND THERAPEUTIC PERSPECTIVES IN DISEASE MANAGEMENT". International Journal of Prevention Practice and Research 02, nr 03 (4.05.2022): 01–05. http://dx.doi.org/10.55640/medscience-abcd614.

Pełny tekst źródła
Streszczenie:
This paper explores the epidemiological landscape and therapeutic interventions related to a specific health concern. Epidemiological studies provide a comprehensive overview of the prevalence, incidence, risk factors, and patterns of this health issue across diverse populations. The discussion delves into the multifaceted nature of epidemiological research, elucidating the role of various factors—genetic, environmental, social, and behavioral—in influencing disease dynamics. Moreover, this paper analyzes therapeutic strategies, encompassing both traditional and innovative approaches, aiming to mitigate the burden of the health concern. Emphasis is placed on evidence-based interventions, advancements in treatment modalities, and their efficacy in improving patient outcomes. The synthesis of epidemiological data with therapeutic interventions forms a critical nexus in shaping public health policies, clinical practices, and future research directions, ultimately contributing to enhanced healthcare delivery and disease management. The interplay between epidemiology and therapeutics is critical in understanding and addressing the dynamics of diseases. Epidemiological studies elucidate the patterns, causes, and risk factors of diseases within populations, providing essential insights into disease transmission, prevalence, and impact. Concurrently, therapeutic interventions aim to alleviate, manage, or eradicate diseases through various modalities such as pharmaceuticals, lifestyle modifications, and behavioral interventions. This abstract explores the intricate relationship between epidemiology and therapeutics, emphasizing their roles in disease prevention, treatment strategies, and public health initiatives. Understanding the epidemiological landscape informs the development and implementation of effective therapeutic approaches, ultimately contributing to improved health outcomes and disease control within communities and globally
Style APA, Harvard, Vancouver, ISO itp.
7

Epstein, Robert S., i Margaret G. McGlynn. "Disease Management". Disease Management & Health Outcomes 1, nr 1 (styczeń 1997): 3–10. http://dx.doi.org/10.2165/00115677-199701010-00002.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Harris, John M. "Disease Management". Disease Management & Health Outcomes 1, nr 1 (styczeń 1997): 11–16. http://dx.doi.org/10.2165/00115677-199701010-00003.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Todd, Warren E., John H. Eichert i Michael R. Toscani. "Disease Management". Disease Management & Health Outcomes 1, nr 1 (styczeń 1997): 26–33. http://dx.doi.org/10.2165/00115677-199701010-00005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

&NA;. "Disease Management". Disease Management & Health Outcomes 2, nr 5 (listopad 1997): 264. http://dx.doi.org/10.2165/00115677-199702050-00011.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

Todd, Warren E., i Edward H. Ladon. "Disease Management". Disease Management and Health Outcomes 3, nr 1 (1998): 1–10. http://dx.doi.org/10.2165/00115677-199803010-00001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

Pleick, Stefanie, i Winfried Sennekamp. "Disease Management". Soziale Arbeit 60, nr 12 (2011): 448–54. http://dx.doi.org/10.5771/0490-1606-2011-12-448.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

Bloor, Karen, i Alan Maynard. "Disease Management". PharmacoEconomics 17, nr 6 (czerwiec 2000): 539–44. http://dx.doi.org/10.2165/00019053-200017060-00001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
14

STAHL, DULCELINA A. "Disease Management". Nursing Management (Springhouse) 27, nr 11 (listopad 1996): 25???30. http://dx.doi.org/10.1097/00006247-199611000-00005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

Cameron, Amanda. "Disease management". PharmacoEconomics & Outcomes News 234, nr 1 (październik 1999): 3–5. http://dx.doi.org/10.1007/bf03275189.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

Cameron, Amanda. "Disease management". PharmacoEconomics & Outcomes News 209, nr 1 (kwiecień 1999): 3–4. http://dx.doi.org/10.1007/bf03319508.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

Short, Robert. "Disease management". PharmacoEconomics & Outcomes News 46, nr 1 (styczeń 1996): 3–4. http://dx.doi.org/10.1007/bf03269769.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

Owen, Mindy. "Disease management". Case Manager 15, nr 3 (maj 2004): 45–47. http://dx.doi.org/10.1016/j.casemgr.2004.04.007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

Schmidlin-von Ziegler, Nicole I. "Disease Management". Medizinische Klinik 93, nr 1 (styczeń 1998): 52–56. http://dx.doi.org/10.1007/bf03045043.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
20

Althaf, Shebin, Manoj Khanal, Anita Rawat i Kishalay Datta. "Devic’s Disease: The Confusing CNS Disease". Indian Journal of Emergency Medicine 9, nr 3 (15.09.2023): 107–9. http://dx.doi.org/10.21088/ijem.2395.311x.9323.10.

Pełny tekst źródła
Streszczenie:
Neuromyelitis optica spectrum is order (NMOSD) is a rare auto-antibody mediated disease of the central nervous system involving the central nervous system. The symptoms should alert the clinician to the diagnosis. Prompt diagnosis in the emergency department plays a crucial role as delay in diagnosis and initiation of management will lead to increased chances of morbidity and mortality. Approximately 80% of NMO patients have auto-antibodies against aquaporin-4, a water channel expressed on astrocytes. In this case report, we discuss a patient with NMO disease, the diagnosis and its management.
Style APA, Harvard, Vancouver, ISO itp.
21

A. de Boer, E. A. M. Joosen, W. "Disease Management in Ulcer Disease". Scandinavian Journal of Gastroenterology 34, nr 230 (styczeń 1999): 23–28. http://dx.doi.org/10.1080/003655299750025507.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
22

Singh, R. K., Akhlak Husen, A. K. Chaudhary i R. K. Maurya. "Clinical profile and management of benign breast disease". Asian Pacific Journal of Health Sciences 7, nr 1 (30.03.2020): 81–85. http://dx.doi.org/10.21276/apjhs.2020.7.1.15.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

Chanda, Ipsita. "COVID-19 Pandemic: Disease Management and Current Therapeutics". Journal of Communicable Diseases 52, nr 04 (31.12.2020): 29–34. http://dx.doi.org/10.24321/0019.5138.202037.

Pełny tekst źródła
Streszczenie:
The highly contagious disease COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic. The high rate of contact transmission of this virus is the major cause of concern nowadays. Owing to the absence of any effective drugs/vaccines against COVID-19, many countries adopted ‘lockdown’ to minimize transmission of virus. The other means that was applied during lockdown, to mitigate the growth of infection is the ‘test, trace, track and isolate’. However, different countries responded differently to these control measures with different outcome in the growth of infection. For now, several countries have started ‘unlock’, to handle the severe economic stress, created in response to lockdown. Again, lifting lockdown is another global threat, having the chance of second wave of infection. In such situation, the major challenge is to prevent the spread of infection, amid resumption of work. The present review is aimed to outline the prospect and future direction of disease management and current therapeutics against COVID-19.
Style APA, Harvard, Vancouver, ISO itp.
24

Goel, Amit, Vinod Kumar, Rahul Rohitaj, MD Najim, Vinod Kumar Singh i P. K. Ganguly. "Management of Gastroesophageal Reflux Disease: A Prospective Study". New Indian Journal of Surgery 6, nr 2 (2019): 151–54. http://dx.doi.org/10.21088/nijs.0976.4747.10219.4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

MS, Hafeza, i Vanitha Palanisamy. "Kimura Disease of the Parotid Gland: Management Approach". Journal of Clinical Otorhinolaryngology 4, nr 1 (4.01.2022): 01–03. http://dx.doi.org/10.31579/2692-9562/038.

Pełny tekst źródła
Streszczenie:
Here we present a 43-years old Malay man with Kimura’s disease of the right parotid gland. Asian men have a predisposition for this chronic inflammatory disorder of unknown etiology mostly presenting at the head and neck region. The management in dealing with this patient is not straight forward as the presentation mimics a subcutaneous tumor-like mass in which main differential diagnosis includes lymphoproliferative disorders and parotid neoplasm. Moreover, cytological investigation is inadequate, and this necessitates the use intra-operative frozen section prior to tumor debulking. Without proper investigation, misdiagnosis can occur and potentially expose the patient to unnecessary extensive surgical procedures. Here we discuss step by step approach in managing this patient.
Style APA, Harvard, Vancouver, ISO itp.
26

Somasundaram, Dr Deepa Subbiah, Dr Salim K. Ismail, Dr Firdous Jahan, Dr Ganji Shivalingam i Dr Kallesh Hebbal. "Kawasaki Disease – Diagnosis and Management- A Retrospective Study". Saudi Journal of Medical and Pharmaceutical Sciences 2, nr 6 (czerwiec 2016): 149–55. http://dx.doi.org/10.21276/sjmps.2016.2.6.6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
27

Pimperkhede, Ms Dipali R., Mr Vaibhav i G. Kute. "A Systemic Review on Management of Alzheimer’s Disease". International Journal of Research Publication and Reviews 4, nr 4 (23.04.2023): 4637–45. http://dx.doi.org/10.55248/gengpi.4.423.38127.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Golovach, I. Yu, i Ye D. Yehudina. "Perygravid management of rheumatic disease". HEALTH OF WOMAN, nr 2(148) (30.03.2020): 42–51. http://dx.doi.org/10.15574/hw.2020.148.42.

Pełny tekst źródła
Streszczenie:
Management of inflammatory rheumatic diseases in preconception period, pregnancy and breastfeeding has undergone significant changes over the past few years. Modern therapy, including biological and targeted synthetic disease modifying drugs, has significantly improved the control of rheumatic diseases, which has led to an increase in the patients’ number planning a pregnancy with serious diseases. When consulting such patients, it is necessary to discuss the possible time of conception (regarding the activity of the disease), the effect of the disease on pregnancy and pregnancy on the disease, as well as the potential need to change the regimen of medications during pregnancy and breastfeeding. This review summarizes information on the effects of pregnancy on various rheumatic diseases and vice versa, changes in therapy and monitoring of patients with rheumatic diseases before, during and after pregnancy. Women with inflammatory rheumatic diseases need advice on drug therapy before planning pregnancy, during pregnancy, and breastfeeding. Safe disease-modifying drugs that can be taken during pregnancy are hydroxychloroquine, sulfosalazine, azathioprine, and cyclosporine. Glucocorticoids and non-steroidal anti-inflammatory drugs can also be taken up to 32 weeks of gestation. Most inhibitors of tumor necrosis factor (anti-TNF) are also safe during pregnancy. During pregnancy, a clear monitoring of the activity of the disease is necessary, control of the level of autoantibodies, especially anti-SSA / Ro and anti-SSB / La and antiphospholipid antibodies, an assessment of the degree of organ dysfunction, especially kidney damage. Presented are modern approaches to optimizing the management of inflammatory rheumatic disease during pregnancy. For patients with inflammatory rheumatic diseases, a successful pregnancy outcome is optimized by creating an individual plan to suppress disease activity using a targeted approach. Key words: pregnancy, rheumatic diseases, treatment, lactation, management tactics, drugs.
Style APA, Harvard, Vancouver, ISO itp.
29

L., J. F. "DISEASE AND WELLNESS MANAGEMENT FIRMS!?" Pediatrics 96, nr 5 (1.11.1995): A62. http://dx.doi.org/10.1542/peds.96.5.a62.

Pełny tekst źródła
Streszczenie:
In 1993 Eli Lilly publicly announced that it was turning itself from a drug firm into a "disease-management" one. The idea is that rather than focusing a company on a specific part of the health-care market, such as drugs or hospitals, a firm should deal with all aspects of a disease. Chronic diseases that require lots of attention could produce the biggest savings (and hence profits). Eli Lilly has launched five disease-management programmes, for asthma, pulmonary disease, depression, diabetes, and ulcers. Several small firms are already thriving in "disease management"... The "wellness-management" school is led by KPMG and Andersen Consulting. They believe that the disease-management approach fails in several respects. Health care involves maintaining health as well as treating diseases; patients often suffer from several diseases, which cannot easily be isolated and managed separately; and "disease-management" is an unappealing notion for companies that want to associate themselves with health, not illness. Instead, companies that promote "wellness" should organize their product portfolios around groups of patients, trying to deal with all their medical needs. Some drug firms are doing this.
Style APA, Harvard, Vancouver, ISO itp.
30

Selecky, Christobel E. "Disease Management of Chronic Obstructive Pulmonary Disease from a Disease Management Organization Perspective". Disease Management & Health Outcomes 16, nr 5 (2008): 319–25. http://dx.doi.org/10.2165/0115677-200816050-00008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Deutman, Robert. "DISC DISEASE MANAGEMENT". Orthopedics 14, nr 4 (kwiecień 1991): 415. http://dx.doi.org/10.3928/0147-7447-19910401-04.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

&NA;. "Disease Management Programmes". Disease Management & Health Outcomes 2, nr 2 (sierpień 1997): 108. http://dx.doi.org/10.2165/00115677-199702020-00009.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

Calhoun, Janet, i Henriette Coetzer. "Respiratory Disease Management". Disease Management and Health Outcomes 9, Supplement 1 (2001): 21–27. http://dx.doi.org/10.2165/00115677-200109001-00004.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

&NA;. "Disease Management Update". Disease Management and Health Outcomes 10, nr 1 (2002): 71–73. http://dx.doi.org/10.2165/00115677-200210010-00006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

&NA;. "Disease Management Update". Disease Management and Health Outcomes 10, nr 2 (2002): 137–40. http://dx.doi.org/10.2165/00115677-200210020-00010.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

&NA;. "Disease Management Update". Disease Management and Health Outcomes 10, nr 3 (2002): 201–4. http://dx.doi.org/10.2165/00115677-200210030-00008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

&NA;. "Disease Management Update". Disease Management and Health Outcomes 10, nr 4 (2002): 263–67. http://dx.doi.org/10.2165/00115677-200210040-00009.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

&NA;. "Disease Management Update". Disease Management and Health Outcomes 10, nr 5 (2002): 327–31. http://dx.doi.org/10.2165/00115677-200210050-00005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
39

&NA;. "Disease Management Update". Disease Management & Health Outcomes 10, nr 6 (2002): 385–94. http://dx.doi.org/10.2165/00115677-200210060-00007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
40

&NA;. "Disease Management Update". Disease Management & Health Outcomes 10, nr 7 (2002): 453–60. http://dx.doi.org/10.2165/00115677-200210070-00005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
41

Shelton, Paul S. "Disease Management Programs". Disease Management & Health Outcomes 10, nr 8 (2002): 461–67. http://dx.doi.org/10.2165/00115677-200210080-00001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
42

&NA;. "Disease Management Update". Disease Management & Health Outcomes 10, nr 8 (2002): 515–25. http://dx.doi.org/10.2165/00115677-200210080-00008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
43

&NA;. "Disease Management Update". Disease Management & Health Outcomes 10, nr 9 (2002): 589–600. http://dx.doi.org/10.2165/00115677-200210090-00007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
44

&NA;. "Disease Management Update". Disease Management & Health Outcomes 10, nr 10 (2002): 661–72. http://dx.doi.org/10.2165/00115677-200210100-00006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
45

&NA;. "Disease Management Update". Disease Management & Health Outcomes 10, nr 11 (2002): 731–39. http://dx.doi.org/10.2165/00115677-200210110-00007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
46

&NA;. "Disease Management Update". Disease Management & Health Outcomes 10, nr 12 (2002): 811–18. http://dx.doi.org/10.2165/00115677-200210120-00007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
47

&NA;. "Disease Management Update". Disease Management & Health Outcomes 11, nr 1 (2003): 61–70. http://dx.doi.org/10.2165/00115677-200311010-00008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
48

&NA;. "Disease Management Update". Disease Management & Health Outcomes 11, nr 2 (2003): 129–37. http://dx.doi.org/10.2165/00115677-200311020-00007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
49

&NA;. "Disease Management Update". Disease Management & Health Outcomes 11, nr 3 (2003): 197–207. http://dx.doi.org/10.2165/00115677-200311030-00007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

&NA;. "Disease Management Update". Disease Management & Health Outcomes 11, nr 4 (2003): 271–76. http://dx.doi.org/10.2165/00115677-200311040-00007.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany bibliografiami na temat „Disease management” dla innych typów źródeł:
Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii